Trial · NCT07880314
Maternal Fatigue After Postpartum Anemia Treatment With Intravenous Ferric Carboxymaltose and Oral Iron Therapy
NCT07880314, Phase 4, Completed, Pakistan Air Force (PAF) Hospital Islamabad
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Maternal Fatigue After Postpartum Anemia Treatment With Intravenous Ferric Carboxymaltose and Oral Iron Therapy. Trials, record NCT07880314. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880314
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Maternal Fatigue After Postpartum Anemia Treatment With Intravenous Ferric Carboxymaltose and Oral Iron Therapy
- NCT number
- NCT07880314
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 134 participants, actual
- Lead sponsor
- Pakistan Air Force (PAF) Hospital Islamabad
- Conditions
- Postpartum Fatigue, Iron Deficiency Anemia
- Interventions
- INTRAVENOUS FERRIC CARBOXYMALTOSE, oral iron therapy
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | change from baseline in Maternal fatigue total score on the Multidimensional fatigue inventory | baseline, 2 week , 6 weeks post treatment | Maternal fatigue is assessed using Multidimensional Fatigue inventory ,a 20 item self report questionnaire . Each item is rated on 5 point likert scale 1 to 5 .The total fatigue score is calculated by summing all 20 items ,yielding a minimum 20 and maximum score of 100. Higher score represent greater fatigue severity ,indicating a worse clinical outcome. change from baseline is calculated as the post treatment score minus the baseline score |
| Secondary | change from baseline in breastfeeding self efficacy scale short form score | baseline 2 week and 6 week postpartum | Breastfeeding self efficacy assesed through breastfeeding self efficacy scale short form ,a 14 item self report questionaire .Each item is rated on 5 point likert scale ranging from 1( not at all) to 5 (always confident ) .Total scores are derived by summing all 14 item responses, yielding a minimum score of 14 and maximum score of 70 .Higher score means greater breastfeeding self efficacy indicating a better clinical outcome change from baseline is calculated as followup score minus baseline score |
| Secondary | number of participants with treatment emergent adverse effects | 2 week and 6 week posttreatment | safety and tolerability are evaluated by systemically recording all treatment emergent adverse effects and side effects following iron administration, adverse events are monitored by type severity and potential causal relationship to study intervention. . |
| Secondary | change from baseline in depressive symptoms on the Edinberg postnatal depression scale | baseline ,2 weeks and 6 weeks postpartum | Maternal depressive symptoms were assessed using edinberg postnatal depression scale ,a 10 item likert self report questionaire . Each item is score on 4 point scale ranging from 0 to 3 .The total score is calculated by summing 10 items yielding a minimum score of 0 and highest score of 30 .Higher total score represent greater severity of depressive symptoms |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38337452 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880314
GET https://conductscience.org/api/trials/v1/NCT07880314/registered